The present study was directed to investigate the effect of precotreatment with
(E)-N'-(1-(7-hydroxy-2-oxo-2H-chromen-3-yl) ethylidene) benzohydrazide (7-hyd.HC), a novel potent synthesized
coumarin, on
isoproterenol- (ISO-) induced
myocardial infarction (MI) in rats. The
hydrazone compound was characterized by IR, 1D, and 2D NMR analyses. Experimental induction of MI in rats was established by ISO (85 mg/kg/day, s.c) for two consecutive days (6th and 7th days).
7-hyd.HC or
sintrom was given for 7 days prior and simultaneous to ISO injection.
7-hyd.HC offered a cardiopreventive effect by preventing
heart injury marker leakage (LDH, ALT, AST, CK-MB, and
cTn-I) from cardiomyocytes and normalizing cardiac function and ECG pattern, as well as improving
lipid profile (TC, TG,
LDL-C, and HDL-C), which were altered by ISO administration. Moreover,
7-hyd.HC precotreatment significantly mitigated the oxidative stress
biomarkers, as evidenced by the decrease of lipid peroxidation and the increased level of the myocardial GSH level together with the SOD, GSH-Px, and
catalase activities.
7-hyd.HC inhibited the cardiac apoptosis by upregulating the expression of Bcl-2 and downregulating the expression of Bax and
caspase-3 genes. In addition,
7-hyd.HC reduced the elevated
fibrinogen rate and better prevented the myocardial
necrosis and improved the interstitial
edema and neutrophil infiltration than
sintrom. Overall,
7-hyd.HC ameliorated the severity of ISO-induced
myocardial infarction through improving the oxidative status, attenuating apoptosis, and reducing
fibrinogen production. The
7-hyd.HC actions could be mediated by its
antioxidant, antiapoptotic, and anti-inflammatory capacities.